US Patent Issued to Celgene on March 24 for "Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same" (New Jersey Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,837, issued on March 24, was assigned to Celgene Corp. (Summit, N.J.).

"Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same" was invented by Lianfeng Huang (Basking Ridge, N.J.) and Wenju Wu (Warren, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are formulations, processes, solid forms and methods of use (e.g., methods of treating a hematological malignancy) relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-...